MKI67 and cancer: This study integrates single-cell analysis, in vitro experiments, and the development of cancer prediction models to thoroughly characterize the C2 MKI67+ TCs subpopulation, thereby enhancing prospects for early CRC screening, prognostic risk evaluation, and targeted therapy, including the identification of potential biomarkers and therapeutic targets.